Manuel Zahn, founder and managing director of 3R Pharma Consulting will attend the GMP-BERATER Tage 2014. The meeting will see a small group of GMP experts meet and discuss new GMP regulations and will share their experiences at Schloss Reinach, near Freiburg, Germany, 8-9 October 2014.
Formpipe has recieved an order from a Swiss company through a German reseller regarding the ECM product Lasernet. The product enables effective reporting and streamlined document design directly from Microsoft Dynamics AX 2012. The order value amounts to SEK1m.
Formpipe receives a supplementary order from a Danish authority regarding development of an application to further sustain the Danish eGovernment strategy. The order value amounts to SEK 6.4 million.
This hands-on course was developed using the latest techniques, theories and processes to train individuals involved with the design, formulation, unit operations, manufacture, quality control/quality assurance, and bioavailability/bioequivalence of pharmaceutical tablets. The course will take place on 21-23 October, 2014.
Natoli Engineering Company, Inc. will host their most popular technical training course, Basics of tablet manufacturing and troubleshooting, at their state-of-the-art Technical Training Centre in St. Charles, MO. The two-day course was developed using the latest techniques, theories and processes to train tooling technicians, tablet press operators, tablet press maintenance technicians, quality control/quality assurance personnel, research and development, and supervisors. 16-18 September, 2014.
The cross-disciplinary capabilities of Malvern Instruments’ technology are being fully exploited at Queen Mary University London. The Zetasizer Nano, NanoSight Nanoparticle Tracking Analysis (NTA) and Mastersizer 2000 systems are all employed within the university’s multi-disciplinary lab. The instruments serve a wide variety of research groups working in areas as diverse as silica coating formulation through to tissue regeneration, demonstrating the value that Malvern’s robust technology brings throughout the scientific arena.
PRA Health Sciences, Inc. announced today that it has filed a registration statement on Form S-1 with the US Securities and Exchange Commission (SEC) relating to a proposed initial public offering ('IPO') of shares of its common stock by PRA Health Sciences and an affiliate of Kohlberg Kravis Roberts & Co. L.P. (the 'selling stockholder'). The number of shares to be offered and the price range has not yet been determined.
Blue Bell, Pennsylvania will soon be home to PRA Health Sciences' largest office worldwide. PRA, a leading global contract research organisation (CRO), is relocating employees from its Horsham and Fort Washington locations into new modern class A+ office space in Blue Bell. The new office marks the first phase of the relocation plan.
With the publication of the WHO draft proposal for the naming of biologics, what is the potential impact on the business of biosimilars?
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.